Tag Archives: pfizer

MiniMed Shares IPO Pricing; NMPA Approves Sciwind/Pfizer’s Ecnoglutide Injection in Obesity; Novo Appoints New SVP

Three cardiometabolic-related news items have been observed: MiniMed released its IPO pricing and began trading shares on the Nasdaq Global Select Market (view press release); Sciwind/Pfizer received approval for ecnoglutide in China (view press release); and Novo appointed Yan Cai as the new SVP and President of Greater China (view article; view LinkedIn post). Below, FENIX provides highlights and insights on the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Novo Reduces Semaglutide WAC Prices; Pfizer To Commercialize Ecnoglutide in China; Novo Ph2 GGG data; AbbVie Builds Out Obesity Manufacturing; Fortress Sells PRV; Alveus Closes $197M Series A; Beta Bionics FDA Warning Letter; Hims & Hers Q4 ’25 Earnings

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Sciwind Biosciences/Pfizer, AbbVie, Fortress Biotech, Alveus Therapeutics, Beta Bionics, and Hims & Hers. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Thoughts on The TrumpRx Launch: The Future Booking.com of Obesity Drugs?

The White House recently launched TrumpRx.gov (view website), an online platform that allows consumers to search for the lowest available cash-pay prices for their prescription medications (view image below). Importantly, the website itself is not the direct point of purchase for consumers; instead, it is a central hub that informs patients of the available out-of-pocket pricing options before redirecting them to purchase the drug by what appears to be two contrasting pathways (discussed below). Below, FENIX outlines how TrumpRx operates, its potential value creation, and why the platform may disproportionately benefit AOM manufacturers.

This content is for Read Less members only.
Register
Already a member? Log in here

JPM 2026 Day 1: DXCM, ARWR, NVS, ALNY, PFE, SNY, CYTK, MDT, MDGL, REGN; Skye 2026 Corporate Outlook; BioAge NLRP3i Ph1 Data; Kailera Ph3 KaiNETIC Program Update

On the first day of JPM 2026, FENIX has provided coverage of presentations by major CVRM companies, including Dexcom, Arrowhead, Novartis, Alnylam, Pfizer, Sanofi, Cytokinetics, Medtronic, Madrigal, and Regeneron. Additionally, three cardiometabolic-related news items have been observed: Skye Biosciences released its 2026 corporate outlook (view press release); BioAge Labs announced updated Ph1 data of its NLRP3i for CV risk reduction (view press release); and Kailera announced it randomized the first patients in its Ph3 KaiNETIC program (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Madrigal Licenses MASH Assets from Pfizer; Wegovy Pill Available on Amazon; New BI MASH Asset; Alveus Launches as Clinical-Stage Biotech; Zealand Partners for AI Drug Discovery; Lilly Expands TuneLab

A series of cardiometabolic-related news items has been observed from Madrigal/Pfizer, Novo Nordisk, Boehringer Ingelheim, Alveus Therapeutics, Zealand Pharma, and Lilly. Below, FENIX provides highlights and insights into the respective news items, including speculation into BI’s new MASH asset MOA.

This content is for Read Less members only.
Register
Already a member? Log in here

Antag Ph1 Obesity Data; Lilly Zepbound+Taltz PsA Combination Data; Rani Initiates Ph1 Dual Agonist Study; Viking Completes Ph1 VK2735 Maintenance Study Enrollment; Gordian and Pfizer Partner for Obesity Drug Discovery; MannKind Provides 2026 Business Updates

A series of cardiometabolic-related news items has been observed from Antag Therapeutics, Lilly, Rani Therapeutics, Viking Therapeutics, Gordian Biotechnology/Pfizer, and MannKind. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Holiday Hangover: Novo Launches Wegovy Pill; Additional Companies Engage in MFN Deals; Pfizer Initiates Ph3 Obesity Program of MET097i; and More

Over the holiday period, a series of cardiometabolic news items were observed from Novo Nordisk, The White House, Pfizer, Cytokinetics, Resoundant, Sanofi, Skye Biosciences, MetaVia, Dexcom, Abbott, MannKind, BI/Rectify, Ascletis Pharma, Laekna Pharma, CMS, and Caliway Biopharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here